74 results about "Medium-chain triglyceride" patented technology

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The invention relates to the technical field of functional food preparation, and discloses solid soft sweets capable of remarkably relieving asthenopia and a preparation method of the solid soft sweets, and every 100 parts by mass of the soft sweets comprise the following components: 5.8-6.2 parts of lutein ester microcapsules, the wall material of which is starch octenyl succinate with the substitution degree of 0.02-0.04; the emulsifier is lecithin of which the purity is greater than or equal to 90%, and the particle size lt of the emulsifier is 1t; the particle size is 200 nm; 75 to 85 parts of blueberry anthocyanin-VC compound freeze-dried powder; 18 to 22 parts of lycium barbarum polysaccharide; 45 to 55 parts of galactooligosaccharide; 8 to 12 parts of medium chain triglyceride; and a colloid base material. Through collaborative design of a hydrophobic modified wall material and a gradient mixing process, a multi-level protection network of active ingredients is constructed, so that the retention rate of fat-soluble nutrients in the processing and storage period is increased to 90% or above.

Methods improve cognitive functioning, for example, at least one of episodic memory, executive function, or language skills; supporting memory and / or recall; providing energy and / or ketones to the brain; and / or preventing and / or treating mild cognitive impairment (MCI) in an individual. A composition comprising medium chain triglycerides (MCTs) can be administered to the individual in a daily dosage providing from about 15 g to about 45 g MCTs. The MCTs can include from about 51 wt % to about 90 wt % of octanoic acid. The daily dose can be provided in at least two servings, for example, 2 or 3 servings. Each serving can provide about 15 g MCTs and can include octanoic acid and decanoic acid in a weight ratio of, for example, about 60:about 40. The individual can be 65 years or older and / or have mild cognitive impairment (MCI).

The present disclosure provides compositions and methods useful for delivering and encapsulating active agents. The compositions can comprise a polymer and a medium chain triglyceride (MCT) that comprises fatty acids having 6 to 12 carbon atoms. The compositions can encapsulate active agents including an antibacterial, a color compound, a fragrance compound, an active pharmaceutical ingredient (API), an over-the-counter (OTC) ingredient, an antioxidant, a flavinoid, an essential oil, or a combination thereof. In particular, the compositions can encapsulate essential oils. These compositions provide for the gradual and controlled release of active agents, particularly essential oils and can be used in a variety of topical products including insect repellents.

A method of treating exocrine pancreatic insufficiency includes administering to an individual in need thereof (e.g., an individual with cystic fibrosis) an effective amount of an enteral composition having a total protein consisting essentially of hydrolyzed protein and a total fat containing monoacylglycerols (MAG) that are at least about 30 wt. % of the total fat, and the total fat optionally further contains medium chain triglycerides (MCT) and / or fatty acids. In one particular non-limiting embodiment, about 60 wt. % of the total fat is from MCT and about 40 wt. % of the total fat is from MAG; in another particular non-limiting embodiment, the total fat is MAG with free fatty acids (esterified and / or bound) without MCT; and in yet another particular non-limiting embodiment, the total fat is MAG alone without MCT.

The invention belongs to the technical field of biological medicines, and particularly relates to an adjuvant influenza vaccine as well as a preparation method and application thereof. The adjuvant influenza vaccine comprises an influenza virus monovalent stock solution, an adjuvant and a PBS (Phosphate Buffer Solution), the adjuvant is prepared by using mixed oil and an auxiliary agent, wherein the mixed oil comprises squalene, medium chain triglyceride and alpha-tocopherol; the auxiliary agents comprise sorbitan trioleate Span-85, Tween 80 and vitamin E succinic acid polyethylene glycol ester. The prepared adjuvant influenza vaccine is good in immune effect, and especially the overall effect of the tetravalent adjuvant influenza vaccine on four viruses can be improved.

Ready to drink coffee beverages are provided. The beverage comprises coffee; medium chain triglycerides (MCT); high acyl gellan gum; plant-based protein; and buffer wherein coffee is 0.5-2.5 w / w %, and MCT is 5-10 w / w %. The beverage can be refrigerated and shelf-stable in a homogenous state for at least six months at 4, 20 and 30° C.

The invention discloses a stable cyclosporine ophthalmic ultra-micro emulsion, which comprises 0.1% of cyclosporine, 1%-2% of medium chain triglyceride, 0.4%-0.8% of an emulsifier, 2%-3% of glycerol, 0.0005%-0.005% of sitaammonium chloride and sodium hydroxide with a required amount for adjusting the pH value of the emulsion to 6.1-7.9, and the emulsifier is a combination of teloxaben and poloxamer in a weight ratio of 3: 1. The cyclosporin ophthalmic ultra-micro emulsion provided by the invention is smaller in droplet particle size and higher in Zeta potential, is basically not changed after being placed for a long time, and has better stability and better expected drug effect.

The invention relates to the technical field of pharmaceutical preparations, in particular to a self-nano-emulsification drug delivery system as well as a preparation method and related application thereof. The self-nano emulsifying composition comprises total glucosides of paeony, dihydroartemisinin and auxiliary materials, the auxiliary materials comprise, by mass, 10-45% of an oil phase, 20-68% of RH40 and 12-72% of ethyl alcohol, and the oil phase comprises glyceryl monooleate and medium chain triglyceride. Compared with the prior art, the self-nano-emulsion composition provided by the embodiment of the invention carries total glucosides of paeony and hydrophobic dihydroartemisinin together, realizes simultaneous administration of water-insoluble components and water-soluble components, and improves bioavailability.

The invention belongs to the technical field of functional grease preparation, and discloses a preparation method and application of medium-chain and long-chain fatty acid triglyceride. The preparation method comprises the following steps: taking mixed vegetable oil; adding water and heating to obtain an oil-water mixture; filling the immobilized lipase into a glass column with external circulating water heating for preheating; injecting the oil-water mixture from the upper part of the immobilized enzyme column to carry out enzyme hydrolysis reaction; collecting a hydrolyzed oil crude product, and separating free fatty acid; taking medium chain triglyceride, mixing, and injecting into the immobilized enzyme column for esterification reaction; and removing reaction by-products to obtain the medium and long chain fatty acid triglyceride rich in omega-3 / 6 / 9 equilibrium proportion. The product prepared by the method contains medium-chain fatty acid and long-chain fatty acid at the same time, the proportion of different fatty acids is more balanced, the health requirement of a human body on fatty acid intake is met, the immobilized enzyme column technology is used in a solvent-free system, the steps of lipase and oil separation are simplified, the service life of enzyme is remarkably prolonged, and the method is suitable for industrial production. The energy consumption and pollution emission are reduced, the production cost is reduced, and the modern industrial green development concept is met.

The present invention describes a process for preparing an aqueous mesoporous particle composition comprising a lipophilic compound, the process comprising the steps of: a. Providing an emulsifier or emulsifier blend in powder form; b. Mixing one or more oils at a temperature above 40 DEG C at which all oils have become liquid, where the melting temperatures of the oils differ and the mixture comprises at least a sufficient amount of medium chain triglycerides, such that the composition formed in step g has a partially liquid oil phase at a temperature of about 4 DEG C; c. Adding a hydrophobic compound or amphiphilic compound in any hydrophobic solvent to the oil mixture; d. Optionally cooling the mixture to room temperature; e. Adding the emulsifier powder and water to the oil mixture and emulsifying the mixture with optional stirring and heating to 30 DEG C to 40 DEG C; f, performing ultrasonic treatment on the emulsified mixture, and optionally performing mixing or fluidization treatment until the average particle size of the mixture is kept stable; g. Cooling the ultrasonically treated mixture to allow for sufficient time to crystallize; and h. Optionally, performing a second ultrasonic treatment while maintaining the mixture at a low temperature, as well as a composition produced by the above process.

Nutritional supplements and compositions for activating the GLP‑1 peptide and / or other hormones in a subject in order to regulate blood sugar, weight, and hunger of the subject are described in this application. The compositions include a first nutritional supplement containing specific amounts of hydrolyzed yeast, acacia gum powder, citrus bioflavonoids, cinnamon bark, and eggplant whole vegetable. The compositions also include a second nutritional supplement containing specific amounts of medium chain triglycerides, resistant potato starch, resistant tapioca starch, kombucha, guar gum, blueberry juice powder, cranberry fruit powder, and grape seed extract. A third composition includes the first and second nutritional supplements containing these ingredients in sufficient amounts to regulate the GLP‑1 hormone and / or other metabolic hormones. These compositions can increase the total GLP‑1 production up to about 220%. Other embodiments are also described.

A composition for oral care is provided having a medium chain triglyceride a hydrophobic anti-microbial agent, and a hydrophobic flavoring agent.

The present invention provides a composition to increase tear production to relieve irritation from dry eyes, and a method for application of the composition. The composition includes at least 5% menthol and a carrier. The carrier comprises at least one of: a triglyceride oil, a medium chain triglyceride, petroleum jelly, coconut oil, olive oil, beeswax, a wax that is semi-solid at 21 C, a vegetable wax, an animal wax, a petroleum wax, a mineral wax, a synthetic wax, vaseline, lanoline, hydrogenated rosin / glyceryl diisostearate, hydrogenated polyisobutene, polyethylene, fatty acid cholesteryl, higher fatty acid esters, aliphatic alcohols, squalene, polyethyleneglycol, higher fatty acids, animal oil, and vegetable oil. The method includes delivering the composition to a user's eye.

The invention discloses a preparation method of an oil-in-water type probiotic emulsion based on lactoferrin. The preparation method comprises the following steps: by taking a compound of lactoferrin and soybean lecithin as an emulsifier and medium chain triglyceride as an oil phase, dispersing probiotic freeze-dried powder in the oil phase, and carrying out high-speed shearing homogenization on a water phase and the oil phase, so as to obtain the oil-in-water type probiotic emulsion. The process for preparing the emulsion is simple and low in cost, the prepared emulsion can effectively embed the probiotics and has a good protection effect on the probiotics, and the gastrointestinal tolerance and environmental resistance of the probiotics in the emulsion can be improved. As a potential commercial product, the product shelf life can be prolonged, and the application range of probiotics and lactoferrin in the food field is expanded.

The invention belongs to the technical field of ophthalmic gels, and discloses an ophthalmic gel for relieving eye allergy symptoms and a preparation method thereof. The preparation method comprises the following steps: S1, dissolving an active component in a phosphate buffer solution containing polysorbate 80 to prepare an active component solution; s2, mixing the obtained active ingredient solution with medium-chain triglyceride, and carrying out high-speed shearing emulsification treatment to obtain a nano emulsion; s3, mixing polyvinyl alcohol and sodium carboxymethyl cellulose, adding into deionized water, stirring and dissolving, then adding genipin, and carrying out cross-linking reaction to obtain a gel matrix; s4, mixing the obtained nano emulsion with a gel matrix, and performing dispersion treatment under ultrasonic waves; and S5, injecting the mixed system into a mold, and curing to obtain the ophthalmic gel with the pH response characteristic. Through the synergistic effect of nano emulsification and intelligent gel, the problems of sudden drug release, low bioavailability and high irritation of a traditional preparation are solved.

The present disclosure provides consumable compositions comprising a haloalkane and a medium chain triglyceride, methods of preparing the consumable composition, and methods of administering the consumable compositions.

A personal care composition having: a hydrocarbon having 4 to 6 carbons; a fatty ester, a fatty acid, a medium chain triglyceride, a silicone, vitamin E, or a combination of two or more thereof; and one or more surfactants, wherein the personal care composition is self-foaming.

The present disclosure provides compositions and methods useful for delivering and encapsulating active agents. The compositions can comprise a polymer and a medium chain triglyceride (MCT) that comprises fatty acids having 6 to 12 carbon atoms. The compositions can encapsulate active agents including an antibacterial, a color compound, a fragrance compound, an active pharmaceutical ingredient (API), an over-the-counter (OTC) ingredient, an antioxidant, a flavinoid, an essential oil, or a combination thereof. In particular, the compositions can encapsulate essential oils. These compositions provide for the gradual and controlled release of active agents, particularly essential oils and can be used in a variety of topical products including insect repellents.

The present disclosure provides compositions and methods useful for delivering and encapsulating active agents. The compositions can comprise a polymer and a medium chain triglyceride (MCT) that comprises fatty acids having 6 to 12 carbon atoms. The compositions can encapsulate active agents including an antibacterial, a color compound, a fragrance compound, an active pharmaceutical ingredient (API), an over-the-counter (OTC) ingredient, an antioxidant, a flavinoid, an essential oil, or a combination thereof. In particular, the compositions can encapsulate essential oils. These compositions provide for the gradual and controlled release of active agents, particularly essential oils and can be used in a variety of topical products including insect repellents.

This invention relates to the application of edible oils in the production of vitamin D drops, belonging to the field of pharmaceutical preparation technology. This invention uses specific types of edible oils (such as medium-chain triglycerides) as lubricants in the vitamin D drop pelleting process, which can completely solve the problem of liquid paraffin in vitamin D drops while ensuring pellet quality. Among single edible oils, medium-chain triglycerides and soybean oil produce the best pellet quality, while using a combination of medium-chain triglycerides and soybean oil can further improve pellet quality.

The invention provides a cyclosporine bulk drug and a detection method of related substances of oil-in-water emulsion thereof, the method adopts an octadecyl silane bonded silica gel chromatographic column (the front of the column is connected with a stainless steel tube), a mobile phase A is a mixed solution of acetonitrile, a water phase, tert-butyl methyl ether and phosphoric acid in a ratio of 450-480: 490-540: 25-45: 1, and the water phase contains 0.1-0.4% of an ion pair reagent; a mobile phase B is a mixed solution of acetonitrile and 0.2% phosphoric acid water in a ratio of 70: 30-80: 20, and the cyclosporine and five impurities (impurity U, impurity H, impurity dihydroA, impurity D and impurity G) thereof can be distinguished and detected at the same time through specific gradient elution. The method has the advantages of strong specificity, high sensitivity and good repeatability, and can effectively control the content of related substances in the cyclosporine oil-in-water emulsion. The method can be used for detecting the cyclosporine ophthalmic preparation containing the teloxacin and the medium chain triglyceride.

This application relates to the field of veterinary drug formulation technology, and discloses a cat anti-stress oral formulation containing pregabalin and its preparation method. The raw materials include: pregabalin-L-arginine co-ground micronized powder, isostearic acid, medium-chain triglycerides, hydrophobic fumed silica, and anhydrous yeast extract powder. The preparation method includes the following steps: weighing each raw material by mass; dissolving isostearic acid in medium-chain triglycerides by heating and stirring; starting high-speed dispersion under vacuum and constant temperature; introducing pregabalin-L-arginine co-ground micronized powder for reaction; introducing anhydrous yeast extract powder for dispersion; cooling and switching to low-speed stirring; adding hydrophobic fumed silica and running under vacuum; finally, static aging and packaging to obtain the finished product. This invention employs a technical solution of compounding pregabalin-L-arginine co-ground micronized powder, isostearic acid, and hydrophobic fumed silica in the oil phase, achieving the technical effect of thixotropic formulation and long-term static non-sedimentation.

The invention relates to a lycopene and lutein compounded eye-protecting soft capsule and a production process thereof, and discloses a lycopene and lutein compounded eye-protecting soft capsule which improves the bioavailability and stability of fat-soluble components by optimizing the component proportion and the production process and adopting a high-speed emulsification and antioxidant protection treatment technology. The eye-protecting soft capsule and the production process thereof are used for realizing more efficient retina protection and asthenopia relieving. The composition is characterized by comprising the following components in percentage by mass: 2%-10% of lutein ester, 1%-5% of lycopene, 0.5%-3% of zeaxanthin, 10%-25% of DHA algal oil, 0.5%-2% of vitamin E, 20%-40% of medium chain triglyceride, 30%-40% of gelatin, 15%-25% of glycerol and 15%-25% of purified water.

The present disclosure provides consumable compositions comprising a haloalkane and a medium chain triglyceride, methods of preparing the consumable composition, and methods of administering the consumable compositions.

The present invention discloses a topical formulation composition comprising diethylene glycol monoethyl ether and a medium chain triglyceride, and free of other pharmaceutically active ingredients. Also disclosed is the use of a topical formulation combination in the treatment of alopecia, hair growth and / or for stoma skin protection. The composition is sprayed for external use, has a good curative effect on androgenetic alopecia, and is simple in components. The composition does not contain ethanol, so that the risk of local stimulation is reduced. The composition does not contain plant extracts, and the quality is easy to control. Compared with a PRP therapy and a low-energy laser therapy, the composition is convenient to use, and a patient can use the composition by himself / herself every day without depending on special equipment.

The present invention relates to the field of pharmaceutical technology, specifically to a self-microemulsifying composition containing lamotrigine, its preparation, and application. The self-microemulsifying composition comprises lamotrigine, an oil phase, an emulsifier, and a co-emulsifier. The oil phase comprises monolinolein and medium-chain triglycerides, the emulsifier is polyoxyethylene 40 hydrogenated castor oil, and the co-emulsifiers are PEG400 and diethylene glycol monoethyl ether. Calculated by weight, the composition contains less than or equal to 18.7% lamotrigine, and the oil phase: emulsifier: co-emulsifier ratio is (2.8-3.0): (1.7-2.0): (5.0-5.4). When the self-microemulsifying composition is dispersed in an aqueous medium, the microemulsion formed has a particle size of less than 50 nm or even smaller. The self-microemulsifying composition can be prepared into dosage forms such as capsules, tablets, granules, and thermosensitive gels, and its application in the preparation of anti-epileptic drugs is also discussed.

A method reduces postprandial glucose from a meal. The method includes orally administering to an individual a composition containing medium chain triglycerides (MCT) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The postprandial glucose is reduced relative to postprandial glucose from (i) postprandial glucose from administration of an identically formulated composition containing MCTs at approximately the same time as the administration of the meal and (ii) postprandial glucose from administration of the meal without any MCTs within about one hour before or within about one hour afterward. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.

The invention discloses an accurate energy control and fat reduction special diet composition based on homology of traditional Chinese medicine and food and a preparation method and application thereof.The composition is composed of soybean protein isolate, medium chain triglyceride, konjaku flour, inulin, white kidney bean extract, calcium beta-hydroxy-beta-methyl butyrate and other components, and a scientific formula is formed through accurate proportioning. The preparation method comprises the steps of raw material weighing, step-by-step mixing, granulation or homogenization treatment and the like, firstly, soybean protein isolate and medium chain triglyceride are mixed to prepare a basic protein and fat mixture, then other components are sequentially added, and finally the uniform and fine special diet composition is prepared. The special diet composition can accurately regulate and control energy intake, lipid metabolism is synergistically promoted through ingredients such as medium chain triglyceride, the konjaku flour, the inulin and the probiotics are utilized to enhance satiety and optimize intestinal health, meanwhile, the advantages of the medicinal and edible plant extracts are exerted, and the special diet composition has the effects of traditional Chinese medicine conditioning and modern nutrition.